左半结肠癌与直肠癌的临床病理差异及一线治疗生存结局:ARCAD数据库六项试验2879例汇总分析
该研究汇总ARCAD数据库中2004-2010年六项一线临床试验的2879例转移性结直肠癌患者,比较左半结肠癌与直肠癌的临床病理特征及生存结局。结果显示两组在性别、年龄、转移部位和KRAS突变频率上存在差异,但调整后PFS和OS无显著差异,提示左侧肿瘤起源部位(结肠vs直肠)并非预后因素。
要点
- 左半结肠癌与直肠癌在性别、年龄、肝肺转移模式及KRAS突变频率上存在显著差异。
- 调整混杂因素后,左半结肠癌与直肠癌的PFS和OS无显著差异,起源部位非预后因素。
- 贝伐珠单抗或西妥昔单抗并未对两组间结局比较产生不同影响。
核心结论
- 左侧肿瘤起源部位(左半结肠vs直肠)不是转移性结直肠癌患者一线治疗结局的预后因素。
- 贝伐珠单抗或西妥昔单抗未对左半结肠癌与直肠癌之间的结局比较产生不同影响。
研究设计与样本
- 汇总分析ARCAD数据库中2004-2010年六项一线临床试验(MAX、COIN、FOCUS2、OPUS、CRYSTAL、COIN-B)的2879例转移性结直肠癌患者数据。
- 纳入原发肿瘤起源明确界定的患者,比较左半结肠癌与直肠癌两组,调整患者和肿瘤特征、转移部位及一线方案后分析PFS和OS。
主要发现
- 左半结肠癌患者较直肠癌患者更常为女性(40.1% vs 32.6%;P < 0.0001)且年龄更大(≥70岁:31.0% vs 25.8%;P = 0.0033)。
- 左半结肠癌肝转移率更高(80.9% vs 72.3%,P < 0.0001),肺转移率更低(34.2% vs 53.8%,P < 0.0001)。
- 左半结肠癌KRAS突变频率略低(34.8% vs 40.5%;P = 0.0103)。
- 左半结肠癌与直肠癌的PFS相近(中位7.4 vs 6.9个月;HR 0.92,95%CI 0.87-1.03;P = 0.1998)。
- 左半结肠癌与直肠癌的OS相近(中位17.4 vs 16.6个月;HR 0.99,95%CI 0.91-1.07;P = 0.7597)。
临床怎么用
- 在临床分层和治疗决策中,不宜将左半结肠癌与直肠癌视为预后不同的独立亚组。
- 左半结肠癌与直肠癌在转移模式和分子特征上存在差异,提示随访和评估策略可考虑原发部位特点。
局限性
- 研究为回顾性汇总分析,数据来源于2004-2010年六项临床试验,可能存在选择偏倚。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with left-sided colon tumours have better survival and respond differently to biologics compared with patients with right-sided tumours. Left-sided colon tumours and rectal cancers are often grouped together. Herein, we examined the clinicopathological differences and outcomes between left-sided colon and rectal cancers. PATIENTS AND METHODS: Data from 2879 metastatic colorectal cancer patients enrolled on six first-line clinical trials during 2004-2010 were pooled. Patients were included if the primary tumour origin was clearly defined. Progression-free survival (PFS) and overall survival (OS) were compared in the two groups after adjusting for patient and tumour characteristics, metastatic sites and the first-line regimen. RESULTS: In total, 1374 patients with metastatic left-sided colon cancer and 1505 patients with metastatic rectal cancers were evaluated. Left-sided colon cancer patients were more likely to be female (40.1% versus 32.6%; P < 0.0001) and older (31.0% ≥ 70 years versus 25.8%; P = 0.0033) compared with rectal cancers patients. Patients with left-sided colon cancer had higher rates of liver metastases (80.9% versus 72.3%, P < 0.0001) but lower rates of lung metastases (34.2% versus 53.8%, P < 0.0001). KRAS mutations were slightly less frequent among left-sided tumours (34.8% versus 40.5%; P = 0.0103). Patients with left-sided tumours had approximately similar PFS (median 7.4 versus 6.9 months; hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.87-1.03; P = 0.1998) and OS (median 17.4 versus 16.6 months; HR 0.99, 95% CI 0.91-1.07; P = 0.7597) compared with rectal cancer patients. CONCLUSION: The site of tumour origin within the left side was not prognostic of outcomes. Moreover, neither bevacizumab nor cetuximab impacted, differently, the findings of the comparisons in outcomes between patients with left-sided colon tumours or rectal cancers.
引用
- Salem ME, Yin J, Weinberg BA, et al. Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018. PMID: 30268921. doi:10.1016/j.ejca.2018.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。